Paul Workman

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.

Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Part of UCB SA, Celltech Chiroscience Plc is a research-based pharmaceutical group.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge.

Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd.

Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders.

SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK.

Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK.

Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom.

Spirea Ltd. operates as a healthcare technology company. It develops smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. The company was founded by Myriam Ouberai and is headquartered in arrogate, the United Kingdom.

Qkine Ltd. provides growth factors and bioactive proteins for use in stem cell science and regenerative medicine applications. Its products include Activin A and FGF2. The firm specializes in protein purification, organoids, cytokines, and protein-engineering. The company was founded by Marko Hyvonen and Catherine Elton in 2016 and is headquartered in Cambridge, the United Kingdom.